Review Article

HCV-Related Rheumatic Manifestations and Therapeutic Strategies

Author(s): Marco Sebastiani, Dilia Giuggioli, Michele Colaci, Poupak Fallahi, Laura Gragnani, Alessandro Antonelli, Anna Linda Zignego and Clodoveo Ferri*

Volume 18, Issue 7, 2017

Page: [803 - 810] Pages: 8

DOI: 10.2174/1389450116666150907103622

Price: $65

Abstract

A number of hepatic and extra-hepatic autoimmune disorders may complicate a percentage of patients with hepatitis C virus (HCV) infection that is both hepatotropic and lymphotropic agent; the resulting clinical phenotypes can be grouped into the so-called HCV syndrome. This latter includes various rheumatic disorders that are frequently characterized by clinical or serological overlap; thus, a correct patients’ classification is necessary prior to decide the therapy.

The management of these conditions is particularly difficult, given the coexistence of viral infection and immunological alterations. In this scenario, cryoglobulinemic vasculitis represents the prototype of HCV-related rheumatic disorders that can be treated at different levels by means of etiological (antivirals) and/or pathogenetic and/or symptomatic treatments (rituximab, cyclophosphamide, steroids, plasmapheresis, etc). In clinical practice, the therapeutic strategy should take into account the specific symptoms combination and the severity/activity of the disease, according to each patient’s conditions. This review focuses on the clinico-diagnostic assessments and therapeutical approaches of some rheumatic disorders complicating HCV infection, mainly arthritis, sicca syndrome, and osteosclerosis; while, cryoglobulinemic vasculitis is comprehensively examined in another article of the present issue.

Keywords: Hepatitis C virus, HCV, mixed cryoglobulinemia, vasculitis, arthritis, Sjögren’s syndrome, ostesclerosis, lymphoma, antiviral, rituximab.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy